Company profile
MetalloBio
Metallobio Limited is a UK company with status active founded in 2021.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQ0MDk1NDM4MWFkaXF6a2N4
Published 25 Oct 2024 10:21
Company registered at Companies House
MetalloBio were awarded the funding to spin-out in January 2021. The spinout will work on developing the antimicrobial compound synthesised during Kirsty Smitten's PhD.
MetalloBio researches and develops antimicrobial drug treatments.
Commercial in Confidence
MetalloBio recently received funding for murine studies, there are 2 FTE and 4 0.2FTE employees.
Commercial in Confidence
1 May 2024 to 31 Oct 2025
Antimicrobial resistance, AMR, is globally responsible for 1.2 million annual fatalities. Failure to address the issue by 2050 could result in 10 million deaths per year, costing the global economy £66 trillion. To put this in to context, the predicted death rate for cancer is 8.2 million by the same year. As current antibiotics fail minor injuries, like ...
1 Jun 2023 to 31 May 2024
Antimicrobial resistance, AMR, is globally responsible for 1.2 million annual fatalities. Failure to address the issue by 2050 could result in 10 million deaths per year, costing the global economy £66 trillion. To put this in to context, the predicted death rate for cancer is 8.2 million by the same year. As current antibiotics fail minor injuries, like ...
1 Apr 2023 to 31 Mar 2024
MetalloBio is a University of Sheffield spin-out company co-founded by Dr Kirsty Smitten and Professor Jim Thomas. MetalloBio are developing a new series of antimicrobial compounds. The compounds are being developed as drugs to treat respiratory bacterial infections and as medical device coatings to prevent infections from developing at the medical device...
1 Dec 2022 to 30 Nov 2023
no public description
1 Oct 2022 to 30 Sep 2023
Antimicrobial resistance, AMR, is globally responsible for 1.2 million annual fatalities. Antimicrobial resistance, AMR, is already responsible for 1.2 million annual fatalities. Failure to address the issue by 2050 could result in 10 million deaths per year, costing the global economy £66 trillion. To put this into context, the predicted death rates for ...
1 Sep 2021 to 30 Nov 2022
Antimicrobial resistance (AMR) is globally responsible for 700,000 annual fatalities. Failure to address this issue by 2050 could result in 10 million deaths per year, costing the global economy £66 trillion. To put this into context, the predicted death rate for cancer will be 8.2 million by the same year. As current antibiotics fail minor injuries, like...
